Eric Shaff, Seres CEO
In a new setback, Seres cites Covid impact after deciding to shelve its lead microbiome cancer program
Seven months after a big, come-from-behind win in Phase III for its lead microbiome program, Seres has another setback to report — this time on the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
